Can a gentler antifungal drug protect liver transplant patients from deadly mold without risking organ rejection?
NCT ID NCT07725874
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
Invasive mold infections are a major threat to liver transplant recipients, with mortality rates as high as 90%. The standard treatment, voriconazole, can interfere with anti-rejection drugs, increasing the risk of graft loss. This trial tests whether liposomal amphotericin B (AmBisome) can safely and effectively treat these infections without those dangerous drug interactions. The study will follow 60 liver transplant patients receiving AmBisome in real-world conditions, closely monitoring for side effects like kidney damage and electrolyte imbalances.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal amphotericin B (AmBisome)
- What this could lead to
- If this trial succeeds, it could provide strong evidence for using liposomal amphotericin B as a first-line treatment for invasive mold infections in liver transplant recipients, potentially reducing the risk of graft rejection compared to current alternatives.
- What could go wrong
- This is a small, single-center, real-world study with no fixed dosing, which limits the strength of conclusions. Liposomal amphotericin B can cause kidney damage, electrolyte imbalances, and infusion reactions, especially in already vulnerable transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could spot hidden fungal infections
- Custom 3D-Printed titanium implants could rebuild faces after injury or surgery
- Hospital study tracks deadly fungus and a possible predictor of patient outcomes
- Can a cancer drug wake up immune cells to beat HIV-Related infections?
- Cresemba under the microscope: Real-World safety check for fungal infections
- Tailoring antifungal doses for seniors: a precision approach